MGP
UTHR icon

Metis Global Partners’s United Therapeutics UTHR Stock Holding History

Metis Global Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-403
Closed -$239K – 745
2026
Q1 		$239K Sell
403
-48
-11% -$23.9K 0.01% 672
2025
Q4 		$220K Sell
451
-43
-9% -$20K 0.01% 713
2025
Q3 		$207K Buy
+494
New +$166K ﹤0.01% 728
2025
Q2 		– Sell
-1,600
Closed -$493K – 812
2025
Q1 		$493K Buy
1,600
+170
+12% +$58.3K 0.01% 593
2024
Q4 		$505K Sell
1,430
-74
-5% -$27.2K 0.02% 585
2024
Q3 		$539K Sell
1,504
-95
-6% -$32.1K 0.02% 558
2024
Q2 		$509K Sell
1,599
-57
-3% -$15.1K 0.02% 539
2024
Q1 		$380K Sell
1,656
-27
-2% -$6.09K 0.01% 611
2023
Q4 		$370K Sell
1,683
-131
-7% -$30.2K 0.01% 609
2023
Q3 		$410K Buy
1,814
+103
+6% +$23.7K 0.02% 574
2023
Q2 		$378K Sell
1,711
-65
-4% -$14.4K 0.02% 580
2023
Q1 		$398K Sell
1,776
-765
-30% -$189K 0.03% 534
2022
Q4 		$707K Sell
2,541
-433
-15% -$109K 0.06% 345
2022
Q3 		$623K Sell
2,974
-121
-4% -$27.1K 0.1% 229
2022
Q2 		$730K Buy
+3,095
New +$629K 0.12% 202

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Metis Global Partners's UTHR Position: Q2 2026 in Review

Metis Global Partners sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 403 shares — an estimated $239K sold.

Metis Global Partners first reported a position in UTHR in Q2 2022 and held it in 15 quarters. The position peaked at $730K in Q2 2022. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Metis Global Partners reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Metis Global Partners sold 403 United Therapeutics shares in Q2 2026, an estimated $239K.
  • Metis Global Partners first reported a position in United Therapeutics in Q2 2022 and held it in 15 quarters.
  • Metis Global Partners's United Therapeutics position peaked at $730K in Q2 2022.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Metis Global Partners's 13F filing for Q2 2026, filed 10 Aug 2026.